ClinicalTrials.gg
RecruitingNCT07729969INCOTEMUpdated Nov 17, 2026

Early Cognitive Interventions in Digital Format for Cancer Survivors

An interventional study of Computerized cognitive treatment and Virtual reality cognitive training in Cognitive Impairment, Cognitive Change and Cancer, sponsored by Biogipuzkoa Health Research Institute. Recruiting at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Biogipuzkoa Health Research Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Cognitive Dysfunction with a site in Spain — 44 open to participants now, 61 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.

Planned enrollment
59th of 127
110 · median 100
Started
2026
with 14 others
No phase
91 of 162
27 open now
Primary completion
2028-04
later than 49 of 60 live
Registered
157th of 162
by date

Among the 162 studies in Cognitive Dysfunction with a site in Spain, this one is the 59th largest by planned enrollment of the 127 interventional ones that give a count, is one of 15 that started in 2026, is one of 91 with no phase, reaches primary completion later than 49 of the 60 other live ones, and was the 157th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

44 of the 162 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Cognitive Dysfunction with a site in Spain, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the usability and effectiveness of two professionally supervised home-based cognitive training interventions as part of an early rehabilitation protocol for cancer-related cognitive impairment.

Participants will be randomized to one of the two intervention arms (computerized cognitive intervention or virtual reality cognitive intervention) or to the control group. Participants of the intervention groups will be assessed before and after the 10 weeks intervention or at equivalent time points for the control group. Comparisons between experimental and control participants, and between the participants in the two intervention arms, will be carried out to see which intervention is most effective and accepted.

Read the detailed description

One of the adverse effects of cancer and its treatments is cognitive decline, which can affect up to 70% of patients throughout the course of their cancer journey. This decline leads to significant difficulties in resuming professional or social roles, among others, and to a reduced quality of life. Results from previous studies suggest that cognitive intervention can help restore affected functions. Within the framework of this project, two digital cognitive intervention platforms (BrainHQ and Enhance VR) have been selected because they offer advantages that make them viable, accessible and effective, such as: (1) being based on proven psychological paradigms; (2) providing a sufficient variety of exercises and difficulty levels; and (3) the ability to be administered at home. Virtual reality (VR) is demonstrating its potential in the healthcare field because it could help address the limitations of transfer and adherence in some cognitive intervention programs. In general, the virtual reality interventions are more ecological, so it is expected that the results will translate more effectively to the patient's daily activities. On the other hand, the greater immersion provides by VR increases motivation and, therefore, improves adherence to this type of interventions.

BrainHQ program consists of online exercises that target the following functions: attention, processing speed, memory, spatial orientation, interpersonal skills and intelligence. BrainHQ will be compared with the Enhace VR cognitive intervention, a library of 15 cognitive exercises developed in virtual reality to train and monitor specific cognitive functions (memory, attention, task flexibility, information processing, orientation, and problem-solving) and motor control.

The interventions will be implemented after the completion of cancer treatments (1-6 months post-chemotherapy) with the aim of promoting early detection of cognitive impairment and preventing it from becoming chronic over time. This will help patients resume their previous roles quickly and effectively.

The purpose of this randomized controlled trial is to test the usability and effectiveness of two digital cognitive interventions in cancer survivors in comparison with a control group.

The specific objectives are:

1) To compare the acceptance and adherence of the cognitive interventions. 2) To analyze the preliminary effectiveness of the interventions on patients' cognitive functioning and quality of life at two different time points: 2.A. Upon completion of the interventions 2.B. One year after completion of the interventions

Exploratory objective:

3) Conduct an exploratory cost study of the interventions compared to CAU (Care as Usual) The study is open to patients over 18 years of age with a cancer diagnosis (stages I-III) and subjective complaints of cognitive functioning related to the cancer diagnosis and/or cancer treatments, who completed chemotherapy treatment between 1 and 6 months prior.

After a first usability session at the hospital where the interventions dynamics are introduced, the interventions will be administered remotely under supervision. A psychologist will maintain weekly contact with the participants to check everything is going well.

Participants will be assessed before the intervention begins (T0) and again 10 weeks after (T1), once the intervention has finished. The follow-up assessment (T2) will take place one year after the intervention ends to examine the sustained effects of the intervention programs.

Improving the quality of life for cancer survivors is a global challenge that this project will help to address. The interventions of this project would help to reduce the time required to successfully resume work, family, and social responsibilities.

03

Conditions studied

  • Cognitive Impairment
  • Cognitive Change
  • Cancer

Keywords

  • Cancer Related Cognitive Impairment (CRCI)
  • Digital interventions
  • Computerized Cognitive Training
  • Virtual Reality Cognitive Training (VR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age diagnosed with cancer (stage I-III)
  • Subjective complaints of cognitive functioning related to the diagnosis of cancer and/or cancer treatments
  • Between 1-6 months after completion of chemotherapy treatment
  • To have Wi-Fi and a computer/tablet
  • To sign the form

Exclusion criteria

Exclusion Criteria:

  • Previous history of cancer diagnosis
  • Anticipated change in cancer treatment/general medical treatment during the intervention period
  • Previous diagnosis of cognitive impairment
  • Diagnosis of other neurological or psychiatric diseases
  • Diagnosis of severe untreated depression
  • History of episodes of vertigo, epilepsy or seizures
  • Currently undergoing or having undergone any other type of intervention aimed at improving cognitive functioning (e.g., CRCI workshops)
  • Severe visual or hearing difficulties that may affect the performance of the intervention exercises
  • Inability to speak, understand, read, and write Spanish correctly
  • Failure to sign the form
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Computerized cognitive training - BrainHQ

    The arm will follow the cognitive training program BrainHQ.

    Behavioral: Computerized cognitive treatment

  • Experimental
    Virtual Reality cognitive training - Enhance VR

    The arm will follow the cognitive training program Enhance VR.

    Behavioral: Virtual reality cognitive training

  • No intervention
    Control Group

    The arm will receive usual care with no cognitive intervention

Interventions

  • BehavioralComputerized cognitive treatment

    Online exercises that target the following functions: attention, processing speed, memory, spatial orientation, interpersonal skills and intelligence. Participants will follow an online cognitive training with the BrainHQ program for 10 weeks. Patients will complete exercises that target attention, executive function, memory and processing speed. They will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week for 10 weeks, a total of 25 hours. Training progresses in an adaptive way, based on the progression of the participant.

  • BehavioralVirtual reality cognitive training

    A library of 15 cognitive exercises developed in virtual reality to train and monitor specific cognitive functions (memory, attention, task flexibility, information processing, orientation, and problem-solving) and motor control. Participants will follow a virtual reality cognitive training with the Enhance VR program for 10 weeks. Patients will complete exercises that target attention, executive function, memory and processing speed. Participants will be asked to train approximately 30 minutes per Enhance VR session, 4 times per week for 10 weeks, a total of 20 hours. Training progresses in an adaptive way, based on the progression of the participant.

06

What researchers measure

Primary outcomes

  1. Change in Perceived Cognitive Function

    Functional Assessment of Cancer Therapy-Cognition, FACT-Cog v3 Self-report questionnaire for cancer patients with cognitive problems consisting of 37 items divided in 4 subscales: Perceived Cognitive Impairment (PCI), Perceived Cognitive Abilities (PCA), Comments From Others (OTH), and Impact on Quality of Life (QoL). The items asked for the past 7 days and are rated on a 5-point Likert scale. Higher scores are indicative of a better cognitive function and QoL.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

Secondary outcomes

  1. Adherence

    Sufficient adherence is defined by completing at least 70% of the required exercise levels

    Time frame: Throughout the 10-week intervention

  2. Change in Montreal Cognitive Assessment (MoCA) score

    MoCA: screening tool aiming to detect cognitive impairment. Total score ranges from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention

  3. Change in Hopkins Verbal Learning Test-Revised (HVLT-R) score

    The HVLT-R assesses learning and immediate and delayed verbal memory. The number of words remembered ranges from 0 to 36 (immediate memory) and from 0 to 12 (delayed memory). Higher scores, words remembered, are indicative of better memory.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention

  4. Change in Trail Making Test (TMT) completion time

    Consists of two parts, to connect numbers in ascending order and to alternate connecting numbers and letters in ascending order. The final score is the time taken to complete the task. The longer it takes, the poorer the cognitive performance.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention

  5. Change in Verbal Fluency score

    Consists of phonological fluency (P-M-R) and semantic fluency (animals, fruits and vegetables). Each word correctly given in each category counts as a point. Higher scores mean better verbal fluency.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  6. Change in Digit Span (WAIS-IV) score

    Measures attention (Digits Forward) and working memory (Digits Backward). The participant must repeat a number sequence. Higher scores, total number sequences correctly repeated, indicate better performance.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  7. Change in Symbol Search (WAIS-IV) score

    Measures processing speed. Higher scores, number of correctly correct answers, indicate better processing speed.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  8. Change in CANTAB Reaction Time (RTI)

    Cognitive test (higher score indicating better outcome).

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  9. Change in CANTAB Rapid Visual Information Processin (RVP)

    Cognitive test (higher score indicating better outcome)

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  10. Change in CANTAB Delayed Matching to Sample (DMS)

    Cognitive test (higher score indicating better outcome)

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  11. Change in CANTAB Paired Associated Matching (PAL)

    Cognitive test (higher score indicating better outcome)

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  12. Change in CANTAB Spatial Working Memory (SWM)

    Cognitive test (higher score indicating better outcome)

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  13. Change in CANTAB One Touch Stockings of Cambridge (OTS)

    Cognitive test (higher score indicating better outcome)

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  14. Change in Hopkins Verbal Learning Test-Revised (HVLT-R) score

    Assesses learning and immediate and delayed verbal memory. The number of words remembered ranges from 0 to 36 (immediate memory) and from 0 to 12 (delayed memory). Higher scores, words remembered, are indicative of better memory.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  15. Change in Fatigue

    EORTC - QCL - FA-12, is a 12-item Likert scale. It evaluates the physical, emotional, and cognitive aspects of fatigue and the interference of it with daily activities and social life in the last 7 days. The items range from 1 to 4 with higher values representing higher symptomatology.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  16. Change in overall Quality of Life

    EORTC QLQ-C-30. This assessment consisted of 30 questions addressing several aspects of quality of life in cancer patients (Functioning scales: physical, emotional, social, cognitive and role; Symptoms scales: fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea symptoms, plus financial difficulties and global health status / quality of life scale). For each scale, scores range from 0 to 100, with higher scores indicating good functioning in the functioning scales and more symptoms burden in the symptoms scales.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  17. Change in Work Ability Index (WAI)

    The first two items of the WAI scale rated the current work ability on a Likert scale from 1 to 10 and the current work ability with respect to the physical and the mental demands of the work. On both items higher scores reflect better work ability.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  18. Change in adherence medication

    Morisky Medication Adherence Scale (MMAS-8) (MMAS-8). The scale consists of 8 items. Response choices are "yes" or "no" for items 1-7 and Item 8 has a five-point Likert response scale. Total scores on the MMAS-8 range from 0 to 8, with higher scores meaning higher adherence.

    Time frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.

  19. Patient Satisfaction

    Net Promoter Score (NPS), assesses satisfaction with a specific product or service by asking how likely that person is to recommend it to someone else on a scale of 0 (not at all likely) to 10 (extremely likely). The final score is calculated by dividing the percentage of promoters (those who score 9-10) by the percentage of detractors (those who score 0-6). The NPS range varies between -100 and +100, with a positive score being considered acceptable and the higher the score, the more acceptable it is considered to be. Client Satisfaction Questionnaire (CSQ-8). Likert-based 8-item questionnaire rating overall satisfaction and acceptability. The 8 items are scored on a 4-point scale (total range from 8-32) with higher scores indicating greater acceptability and satisfaction.

    Time frame: Thoughout the 10-week intervention.

  20. Subjective experience with the exercises

    Game Experience Questionnaire (GEQ). The Core Module consists of 33 items which assess game experience on seven components: Immersion, Flow, Competence, Positive and Negative Affect, Tension, and Challenge. Each item is rated from 0 (Not at all) to 4 (Extremely). High score in a concrete dimension means intense experience on that dimension.

    Time frame: At the usability session.

  21. Usability

    System Usability Scale (SUS), is a 10-item self-report measure designed for usability assessment. Items are rated on a 5- 8 point Likert scale (1 = strongly disagree, 5 = strongly agree). Total SUS scores have a range of 0 to 100, being higher scores in the SUS indicative of greater usability.

    Time frame: Thoughout the 10-week intervention.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Zeng Y, Guan Q, Su Y, Huang Q, Zhao J, Wu M, Guo Q, Lyu Q, Zhuang Y, Cheng AS. A self-administered immersive virtual reality tool for assessing cognitive impairment in patients with cancer. Asia Pac J Oncol Nurs. 2023 Feb 28;10(3):100205. doi: 10.1016/j.apjon.2023.100205. eCollection 2023 Mar. PubMed 37012969 ↗
  • Wu LM, Amidi A, Tanenbaum ML, Winkel G, Gordon WA, Hall SJ, Bovbjerg K, Diefenbach MA. Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer. 2018 Jun;26(6):1917-1926. doi: 10.1007/s00520-017-4026-8. Epub 2017 Dec 27. PubMed 29282534 ↗
  • Von Ah D, Crouch A, Storey S. Acceptability of computerized cognitive training and global cognitive stimulating-based games delivered remotely: Results from a randomized controlled trial to address cancer and cancer-related cognitive impairment in breast cancer survivors. Cancer Med. 2023 Jun;12(11):12717-12727. doi: 10.1002/cam4.5904. Epub 2023 Apr 11. PubMed 37039279 ↗
  • Von Ah D, McDonald BC, Crouch AD, Ofner S, Perkins S, Storey S, Considine R, Unverzagt F. Randomized double-masked controlled trial of cognitive training in breast cancer survivors: a preliminary study. Support Care Cancer. 2022 Sep;30(9):7457-7467. doi: 10.1007/s00520-022-07182-4. Epub 2022 Jun 1. PubMed 35648204 ↗
  • Serweta-Pawlik A, Lachowicz M, Zurek A, Rosen B, Zurek G. Evaluating the Effectiveness of Visuospatial Memory Stimulation Using Virtual Reality in Head and Neck Cancer Patients-Pilot Study. Cancers (Basel). 2023 Mar 7;15(6):1639. doi: 10.3390/cancers15061639. PubMed 36980525 ↗
  • Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016 Feb 20;34(6):611-35. doi: 10.1200/JCO.2015.64.3809. Epub 2015 Dec 7. PubMed 26644543 ↗
  • Mayo SJ, Rourke SB, Atenafu EG, Vitorino R, Chen C, Kuruvilla J. Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study. Pilot Feasibility Stud. 2021 Jan 30;7(1):36. doi: 10.1186/s40814-021-00778-3. PubMed 33514444 ↗
  • Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, Joly F. Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey. Cancer Med. 2019 May;8(5):2654-2663. doi: 10.1002/cam4.2069. Epub 2019 Mar 18. PubMed 30884207 ↗
  • Lange M, Joly F. How to Identify and Manage Cognitive Dysfunction After Breast Cancer Treatment. J Oncol Pract. 2017 Dec;13(12):784-790. doi: 10.1200/JOP.2017.026286. PubMed 29232539 ↗
  • Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012 Apr 1;30(10):1080-6. doi: 10.1200/JCO.2011.37.0189. Epub 2012 Feb 27. PubMed 22370315 ↗
  • Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancre V, Lange M, Castel H. Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage. 2015 Dec;50(6):830-41. doi: 10.1016/j.jpainsymman.2015.06.019. Epub 2015 Sep 5. PubMed 26344551 ↗
  • Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014 Feb;26(1):102-13. doi: 10.3109/09540261.2013.864260. PubMed 24716504 ↗
  • Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012 Nov;38(7):926-34. doi: 10.1016/j.ctrv.2012.05.002. Epub 2012 Jun 2. PubMed 22658913 ↗
  • Garcia-Torres F, Tejero-Perea A, Gomez-Solis A, Castillo-Mayen R, Jaen-Moreno MJ, Luque B, Galvez-Lara M, Sanchez-Raya A, Jablonski M, Rodriguez-Alonso B, Aranda E. Effectiveness of the Unified Barlow Protocol (UP) and neuropsychological treatment in cancer survivors for cognitive impairments: study protocol for a randomized controlled trial. Trials. 2022 Sep 30;23(1):819. doi: 10.1186/s13063-022-06731-w. PubMed 36175973 ↗
  • Brugada-Ramentol V, Bozorgzadeh A, Jalali H. Enhance VR: A Multisensory Approach to Cognitive Training and Monitoring. Front Digit Health. 2022 Jun 3;4:916052. doi: 10.3389/fdgth.2022.916052. eCollection 2022. PubMed 35721794 ↗
  • Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, Boyle F, Price MA, Vardy JL. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol. 2017 Jan 10;35(2):217-225. doi: 10.1200/JCO.2016.67.8201. Epub 2016 Oct 28. PubMed 28056205 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2028, 22 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 22 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jul 28, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 removed
What changed in the outcomes
  • RemovedChange in Sleep DisturbanceTime frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
  • RemovedChange in Anxiety and Depression symptomsTime frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Secondary outcomes 2 removed
    What changed in the outcomes
    • RemovedChange in Sleep DisturbanceTime frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
    • RemovedChange in Anxiety and Depression symptomsTime frame: Baseline (before randomization and intervention), after completion of the 10-week intervention, and 1 year after completion of the intervention.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07729969
Lead sponsor
Biogipuzkoa Health Research Institute
Collaborators
Biobizkaia Health Research Institute
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jun 8, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Dr. Ander Urruticoechea Ribate
Contact
ander.urruticoechearibate@osakidetza.eus
+34943328000
Dra. Mari Feli González
Contact
mariafeliciana.gonzalezperez@osakidetza.eus
+34943328380

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion